Tela Bio, Inc. ((TELA)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tela Bio earnings call walks a careful line between optimism and caution, as management emphasized strong early traction across its hernia portfolio, international momentum and a fully staffed U.S. salesforce while acknowledging margin pressure, modest top-line growth and a wider net loss. The tone suggested building momentum and early validation, but with execution risk in achieving the planned second-half acceleration.
Revenue Growth and Updated Guidance
Tela Bio reported Q1 2026 revenue of $19.1 million, a 3% increase from $18.5 million a year ago, underscoring modest headline growth despite multiple initiatives. Management nevertheless reiterated full-year guidance for at least 8% revenue growth over 2025 and set Q2 guidance around $20 million, implying an expected ramp as new reps mature.
International Surge Led by Europe
International revenue climbed 41% year over year to $3.7 million, driven entirely by the hernia portfolio and particularly strong performance in Europe. The U.K. National Health Service selected OviTex for complex abdominal procedures under a value-based scheme, and management stressed that the economic and clinical rationale is transferable across other European health systems.
OviTex Volume Gains and Portfolio Breadth
OviTex revenue reached $12.6 million versus $12.1 million a year ago, backed by robust unit growth of 16% to 5,800 units from 5,000. Executives highlighted that the breadth of the OviTex portfolio allows the company to participate in open, laparoscopic and robotic hernia procedures, positioning it to benefit from shifting surgical trends.
Launch of OviTex LTR Fully Resorbable Line
The company completed the full U.S. commercial launch of OviTex LTR on April 1, describing it as one of the only fully resorbable tissue-based hernia solutions on the market. Priced to preserve the existing value proposition, OviTex LTR has received what management called overwhelmingly positive early field feedback, suggesting another lever for future growth.
Fully Staffed U.S. Commercial Organization
Tela Bio now has its U.S. commercial team staffed to expected 2026 levels, marking the largest field force in its history with more than 90 territory managers and 19 greenfield territories. Roughly 40% of the team was hired between Q4 and Q1, and management expects many of those reps to hit the six-month productivity inflection point by late Q2, supporting anticipated second-half gains.
LiquiFix and Adjunct Product Momentum
LiquiFix, an adjunct product in the portfolio, posted year-over-year growth above 50%, reinforcing its role as a meaningful contributor despite its smaller base. Executives said LiquiFix helps open doors with new surgeons and deepens penetration in existing accounts, complementing the core OviTex franchise.
Expanding Clinical Evidence and Surgeon Support
Management highlighted new clinical evidence, including a meta-analysis presented at a major surgery meeting showing OviTex to be safe and effective with significantly lower recurrence rates versus competitors. They underscored that high-profile authors and real-world data are bolstering the product’s value story, which could aid adoption among surgeons and hospital systems.
Board Refresh to Support Scaling
Tela Bio announced the addition of four new directors with extensive medical technology and commercialization experience, as part of a broader board refresh. The company expects this new slate to provide strategic guidance for scaling the business and advancing toward profitability, signaling an emphasis on governance aligned with the next growth phase.
Gross Profit Holds as Margins Slip
Gross profit in Q1 2026 was $12.5 million, essentially flat versus the prior year despite only modest revenue growth, suggesting an underlying resilient cost structure. However, gross margin slipped to 66% from 68%, which management tied mainly to higher charges for excess and obsolete inventory as a share of revenue.
Limited Top-Line Progress Despite Initiatives
The 3% year-over-year revenue growth to $19.1 million highlights that Tela Bio’s numerous commercial initiatives have yet to translate into substantial top-line acceleration. Investors will likely focus on whether the company can deliver the implied second-half ramp, especially as the expanded salesforce and new products move past early stages.
Net Loss and Interest Expense Increase
Net loss widened to $12.3 million from $11.3 million in the prior-year quarter, reflecting higher non-operating costs. Interest expense rose to $2.1 million from $1.2 million following a larger credit facility put in place late last year, adding pressure to the bottom line even as operating loss remained flat at $10.5 million.
Persistent Operating Loss and High Expenses
Loss from operations stayed at $10.5 million, essentially unchanged year over year, illustrating limited operating leverage in the quarter. Operating expenses totaled $23.0 million, including $16.5 million for sales and marketing, $4.2 million for general and administrative and $2.3 million for research and development, reflecting continued investment ahead of expected revenue gains.
PRS Utilization Volatility and Concentration Risk
OviTex PRS revenue slipped slightly to $5.9 million from $6.0 million, as utilization dipped due to the temporary absence of several high-volume implanters. Management acknowledged that reliance on a small number of high-ASP users introduces concentration risk, stressing the need to broaden the PRS user base to stabilize growth.
Average Selling Price Pressure from Mix Shift
Dollar growth in OviTex was partly muted by a shift toward smaller-sized units, which compressed average selling prices even as volumes climbed. This mix effect reduced revenue per unit and illustrates how product configuration trends can blunt headline growth, even in the face of strong procedural adoption.
Cash Position and Need for Execution
The company ended the quarter with $39.5 million in cash and cash equivalents, a level that management did not characterize as a near-term concern. However, the combination of ongoing operating losses and rising interest costs underscores how crucial it is for Tela Bio to realize its planned commercial ramp and move closer to break-even over time.
Forward-Looking Guidance and Execution Drivers
Management reaffirmed guidance for at least 8% revenue growth in 2026 and forecast Q2 revenue around $20 million, implying a stronger second half than the start of the year. They flagged key variables around territory realignments, contract execution and the maturation of newly hired reps, noting these factors could drive upside or downside relative to the target and emphasizing confidence but also clear execution dependence.
Tela Bio’s latest earnings call paints a picture of a company in transition, with strong product momentum and expanding international reach offset by modest near-term growth, margin pressure and persistent losses. For investors, the story now hinges on whether a fully built salesforce, new product launches and strengthening clinical data can translate into the back-half acceleration management has promised.